Impact of pharmacy channel on adherence to oral oncolytics

Table 5 Logistic regression model: adherence to index oral oncolytic^a

Determinant	Odds Ratio	95% CI
Age, Reference <65 Years
≥ 65 years	1.04	0.98–1.09
Gender, Reference Female
Male	1.15	1.09–1.21
Geographic Region, Reference South
Northeast	0.93	0.87–0.99
Midwest	1.12	1.04–1.20
West	0.97	0.90–1.05
Unknown	1.02	0.87–1.18
Population, Reference Retail Pharmacy
Specialty	1.99	1.87–2.11
Copay, Reference $0–49
$50–100	0.74	0.69–0.80
$101–150	0.83	0.75–0.92
$151–200	0.74	0.65–0.86
$201–250	0.65	0.55–0.77
$251–350	0.89	0.75–1.06
$351–500	0.93	0.80–1.09
$501–1000	0.92	0.83–1.02
> $1000	0.74	0.65–0.83
Prescription Days of Supply, Reference ≤30
31-89	0.28	0.26-0.30
90+	1.66	1.35-2.03
Index Oncolytic, Reference Erlotinib
Capecitabine	0.16	0.15-0.17
Imatinib	0.53	0.49-0.58

Note: patients assumed to be adherent if proportion of days covered ≥80%, Mean p[adherence] for SP = 0.76, Mean p[adherence] for TR = 0.59, Mean p[adherence] for patients receiving erlotinib = 0.83, Mean p[adherence] for patients receiving capecitabine = 0.42, Mean p[adherence] for patients receiving imatinib = 0.70
Abbreviations: CI confidence interval, P[adherence], predicted probability of adherence
^aBased on the proportion of days covered between first and last fill of index oncolytic, analysis includes patients who filled their index oncolytic >1 time as adherence could only be measured for these patients

ISSN: 1472-6963